Pressemitteilung BoxID: 379876 (Cytori Therapeutics, Inc.)
  • Cytori Therapeutics, Inc.
  • Top Gun Street
  • 6740 San Diego

Cytori Therapeutics Prices Public Offering of Common Stock

(PresseBox) (San Diego, ) Cytori Therapeutics (NASDAQ: CYTX) is selling 4,000,000 shares of its common stock at a price to the public of $4.50 per share. The net proceeds from the sale of the shares, after underwriting discounts and commissions and other offering expenses, are expected to be approximately $16.8 million.

Cytori anticipates using the net proceeds from the offering for general corporate purposes, including sales and marketing activities, clinical studies, research and development, capital expenditures, future acquisitions, working capital and repayment of debt.

The offering is expected to close on or about October 13, 2010, subject to customary closing conditions. Jefferies & Company, Inc. is acting as sole book-running manager for this offering. Cytori has granted the underwriter a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock to cover over-allotments, if any.

Registration statements relating to the securities described above have become effective by order or rule of the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website located at Copies of the final prospectus supplement relating to these securities, when available, may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Cytori Therapeutics, Inc.

Cytori develops and commercializes medical technologies that enable the practice of regenerative medicine.